sb 203580 has been researched along with pyrogallol in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (pyrogallol) | Trials (pyrogallol) | Recent Studies (post-2010) (pyrogallol) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 1,243 | 6 | 351 |
| Protein | Taxonomy | sb 203580 (IC50) | pyrogallol (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 1.23 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 0.997 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.114 | |
| Autoinducer 2-binding periplasmic protein LuxP | Vibrio harveyi | 2 | |
| 5-lipoxygenase | Bos taurus (cattle) | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Esberg, LB; Ren, J | 1 |
1 other study(ies) available for sb 203580 and pyrogallol
| Article | Year |
|---|---|
The oxygen radical generator pyrogallol impairs cardiomyocyte contractile function via a superoxide and p38 MAP kinase-dependent pathway: protection by anisodamine and tetramethylpyrazine.
Topics: Animals; Dose-Response Relationship, Drug; Drug Antagonism; Drugs, Chinese Herbal; Enzyme Inhibitors; Free Radical Scavengers; Imidazoles; Male; Myocardial Contraction; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Pyrazines; Pyridines; Pyrogallol; Rats; Rats, Sprague-Dawley; Solanaceous Alkaloids; Superoxide Dismutase; Superoxides | 2004 |